Cytocom, Inc.
↗Fort Collins, Colorado, USA
Cytocom, Inc., which rebranded to Statera BioPharma, Inc. in September 2021, is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company specializes in toll-like receptor (TLR) agonists, with one of the largest platforms of TLR4, TLR5 and TLR9 agonists in the biopharmaceutical industry. Founded in 2014 in Fort Collins, Colorado, the company was acquired by publicly-traded Cleveland BioLabs in a reverse merger transaction in July 2021, becoming a NASDAQ-traded entity. The company subsequently completed the acquisition of ImQuest Life Sciences and its subsidiaries in June 2021.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Immunotherapies, Toll-Like Receptor Agonists
SIZE & FINANCIALS
Employees:1-50
Revenue:<$5M
Founded:2014
Ownership:public
Status:operating
FUNDING
Stage:Clinical Stage
Total Raised:$90M+
Investors:GEM Global Yield LLC SCS ($75M equity), Avenue Capital, Adit Ventures
STOCK
Exchange:NASDAQ/OTC
Ticker:STAB (formerly CBLI)
PIPELINE
Stage:Phase 2/Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule, Toll-like Receptor (TLR) Agonists, Immunomodulators
Active Trials:3
Trial Phases:Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Acquired By:Cleveland BioLabs, Inc. (reverse merger) (2021-07-01)
Subsidiaries:ImQuest BioSciences (acquired June 2021), ImQuest Pharmaceuticals (merged into operations)
Key Partnerships:ICON plc: Managing Phase 3 STAT-201 trial for pediatric Crohn's disease, Tivic Health Systems: Exclusive worldwide rights to Entolimod for acute radiation syndrome (2025), Immune Therapeutics Inc.: Strategic agreement for naltrexone and met-enkephalin rights, Biostax Corp.: Exclusive rights to low-dose naltrexone patents for all indications except Crohn's disease
COMPETITION
Position:Niche Player
Competitors:Adaptive Biotechnologies, Dynavax Technologies, Denali Therapeutics, Rigel Pharmaceuticals, Syndax Pharmaceuticals
LEADERSHIP
Key Executives:
Michael K. Handley - President and CEO
Peter Aronstam - Chief Financial Officer
Taunia Markvicka - Chief Operating Officer
Dr. Robert W. Buckheit, Jr. - Chief Technical Officer and President/Chief Scientific Officer of ImQuest BioSciences
LINKS
Website:cytocom.com
Crunchbase:Crunchbase Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Cytocom, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.